- Home
- BIIB vs QSR Comparison
BIIB vs QSR Comparison
Compare BIIB & QSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- QSR
- Stock Information
- Founded
- BIIB 1978
- QSR 1954
- Country
- BIIB United States
- QSR Canada
- Employees
- BIIB N/A
- QSR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- QSR
- Sector
- BIIB Health Care
- QSR
- Exchange
- BIIB Nasdaq
- QSR Nasdaq
- Market Cap
- BIIB 18.8B
- QSR N/A
- IPO Year
- BIIB 1991
- QSR 2006
- Fundamental
- Price
- BIIB $132.82
- QSR $68.70
- Analyst Decision
- BIIB Buy
- QSR Buy
- Analyst Count
- BIIB 27
- QSR 19
- Target Price
- BIIB $188.17
- QSR $77.74
- AVG Volume (30 Days)
- BIIB 1.3M
- QSR 4.2M
- Earning Date
- BIIB 07-31-2025
- QSR 08-07-2025
- Dividend Yield
- BIIB N/A
- QSR 3.60%
- EPS Growth
- BIIB 26.39
- QSR N/A
- EPS
- BIIB 10.12
- QSR 2.94
- Revenue
- BIIB $9,816,400,000.00
- QSR $8,776,000,000.00
- Revenue This Year
- BIIB N/A
- QSR $9.51
- Revenue Next Year
- BIIB N/A
- QSR $3.22
- P/E Ratio
- BIIB $13.13
- QSR $23.42
- Revenue Growth
- BIIB 1.59
- QSR 22.38
- 52 Week Low
- BIIB $110.04
- QSR $58.71
- 52 Week High
- BIIB $238.00
- QSR $75.07
- Technical
- Relative Strength Index (RSI)
- BIIB 59.57
- QSR 57.66
- Support Level
- BIIB $123.90
- QSR $64.44
- Resistance Level
- BIIB $134.75
- QSR $68.49
- Average True Range (ATR)
- BIIB 3.50
- QSR 1.10
- MACD
- BIIB 0.28
- QSR 0.20
- Stochastic Oscillator
- BIIB 83.71
- QSR 98.68
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.